Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Ocean Biomedical, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2023
FY2024
Research and development
8.41
0.71
0.03
General and administrative
7.71
9.51
3.77
Operating expenses
16.1
10.2
3.8
Operating income
-16.1
-10.2
-3.8
Interest expense
0
0.05
Interest income
1.52
Other non-operating income
-1.24
-104
-5.68
Net income
-17.4
-114
-9.48
EPS, basic
-0.74
-4.35
-0.34
EPS, diluted
-0.74
-4.35
-0.34
Shares, basic (weighted)
23.4
26.3
27.5
Shares, diluted (weighted)
23.4
26.3
27.5
Balance sheet
FY2022
FY2023
FY2024
Cash and equivalents
0.03
1
0.2
Other current assets
0.09
1.11
0.59
Total current assets
1.84
2.11
0.81
Total assets
1.84
5.5
0.9
Accounts payable
11.4
16.2
15.9
Accrued liabilities
0.45
0.95
Short-term debt
0.78
3.2
Total current liabilities
12.7
30
33.9
Total liabilities
12.7
96.3
98.5
Paid-in capital
70.8
105
108
Retained earnings
-81.6
-196
-206
Shareholders' equity
-10.8
-90.8
-97.6
Total equity
-10.8
-90.8
-97.6
Total liabilities and equity
1.84
5.5
0.9
Shares outstanding
23.4
34.6
34.9
Cash flow statement
FY2022
FY2023
FY2024
Net income
-17.4
-114
-9.48
Stock-based compensation
12.4
1.21
0.75
Change in payables
0.29
1.23
0.87
Cash from operations
-0.99
-9.43
-4.18
Purchases of investments
-2.1
Cash from investing
-2.1
Debt issued
2.1
Stock issued
14.3
Cash from financing
0.97
10.4
3.4
Net change in cash
-0.03
0.97
-0.78
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2025; growth uses fiscal years. Valuation uses the share price of $0.00 on November 9, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-1,942.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-83.6%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
4.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.06x
Current assets / current liabilities.
Quick ratio
0.03x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.03x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.04
Cash from operations / diluted weighted shares.
Book value per share
-$0.56
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-132,199.0%
Net income / market cap (the inverse of P/E).
Was Ocean Biomedical, Inc. profitable in fiscal 2024?
No. It reported a net loss of $9.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.